Surgical resection (NCT05535166)

Name: Surgical resection trial for Medulloblastoma (NCT05535166)
Uploaded: 2026-10-31T22:38:22.360Z
Duration: 1 min 35 s
Description: Surgical resection trial for Medulloblastoma (NCT05535166). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05535166.

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma: a one-minute explainerNCT055351661 min

Surgical resection trial for Medulloblastoma (NCT05535166). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for children under three with specified medulloblastoma molecular types, or ages three to four with nonmetastatic SHH-2 medulloblastoma, after surgery. Central tumor testing determines eligibility.

The idea: tailor methotrexate-based chemotherapy to tumor biology. Methotrexate blocks DNA production. SHH-2 groups use chemotherapy alone; other eligible SHH groups also receive it into brain ventricles. Eligible non-SHH groups delay brain-and-spine radiation until age three. Researchers assess progression and development.

This phase 2 study plans 130 patients. St. Jude’s Giles Robinson and Aditi Bagchi lead it; ten US sites are recruiting, including Memphis.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.